RaySearch Laboratories AB (publ) has entered into a licensing and distribution agreement with TAE Life Sciences, manufacturer of the Alphabeam™ System for boron neutron capture therapy (BNCT).
BNCT is a biologically targeted radiation therapy that kills cancer at the cellular level. The technique uses a two-step process. In the first step, patients are injected with a tumor-targeting drug that contains non-toxic and non-radioactive boron-10. In the second step, the target area is exposed to low-energy neutrons. When the boron-10 and neutrons interact, short-range, high-energy charged particles are emitted that systemically destroy tumor cells - with minimal damage to adjacent healthy tissue and low risk of side effects. BNCT is therefore an attractive treatment modality for complicated and recurrent cancers, such as glioblastomas or head and neck cancers.
The combination of worldwide clinical interest in BNCT, advanced boron agents, modern accelerator-based neutron production technology and innovative software is paving the way for a new era in BNCT to help the fight against cancer.
The RayStation treatment planning system supports BNCT treatment planning* with tools for contouring, image importing, reporting, plan creation and evaluation, as well as support for defining BNCT-specific models of relative biological effectiveness. Under the agreement, RayStation will work in conjunction with TAE Life Sciences' proprietary dose calculation software for the Alphabeam System, which can be configured for single- or multi-room BNCT centers.
Bruce Bauer, CEO, TAE Life Sciences, says: "The new era of accelerator-based BNCT offers a highly promising therapy for hard-to-treat cancers, both in effectiveness and reduced treatment time. We are excited to partner with RaySearch on the integration of RayStation with our compact Alphabeam System. Our partnership will help accelerate the commercialization of hospital-based BNCT and greatly benefit clinicians and cancer patients globally."
Johan Löf, founder and CEO, RaySearch, says: "BNCT is gaining ground as an option for certain types of tumors, and we are keen to support partner companies operating in this field of radiation therapy. I am pleased to share the news of our partnership with TAE Life Sciences to advance cancer treatment."
About TAE Life Sciences
TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT). TLS is developing the next generation targeted boron drugs and low-energy, accelerator-based neutron source - optimized for an in-hospital BNCT program that will one day treat patients with the most aggressive and recurrent cancers. TLS has assembled a world-class cross-functional team of clinicians, radiation oncologists, physicists and other researchers to bring its technology to the cancer patients who need it most. TLS's drug and device are currently in development and have not been approved for sale. More information about TAE Life Sciences is available at www.taelifesciences.com.
RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets worldwide its treatment planning system RayStation and next-generation oncology information system RayCare*. Over 2,600 clinics in more than 65 countries use RaySearch software to improve life and outcomes for patients. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003. More information about RaySearch is available at www.raysearchlabs.com.
RayStation is a flexible, innovative treatment planning system, chosen by many of the leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for IMRT and VMAT optimization with highly accurate dose engines for photon, electron, proton and carbon ion therapy. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare. By harmonizing the treatment planning, we enable better care for cancer patients worldwide.
* Subject to regulatory clearance in some markets.
This order was received in Q2/2020.
For further information, please contact:
Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
Peter Thysell, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)70 661 05 59